[Tetracosactide (Synacthen Depot) in patients with multiple sclerosis].
In a group of 292 patients, clinically definite cases of multiple sclerosis, 91 of them were administered Tetracosactrin (Synacthen Depot) during the initial or exacerbation attack of the disease. Two female patients developed typical anaphylaxis during the drug use: the first patient after the twenty-second injection and the second one after the sixth injection. Negativity of the cutaneous test to zinc oxide in these two female patients, increased IgE immunoglobulin concentration and positive RAST to the drug suggested to the feature of immediate allergy conditioned by reagins.
Kanić
M
M
Neurologische Klinik, Universitätspital, Zürich, Schweiz.
Sepcić
J
J
D000328:Adult; D000707:Anaphylaxis / Q000139:chemically induced*; D003366:Cosyntropin / Q000009:adverse effects* / Q000627:therapeutic use; D003692:Delayed-Action Preparations; D004342:Drug Hypersensitivity; D005260:Female; D006801:Humans; D009103:Multiple Sclerosis / Q000188:drug therapy*
D003692:Delayed-Action Preparations; D003366:Cosyntropin; C006418:adrenocorticotropin zinc
Alergija na tetrakozaktid (Synacthen depot) u oboljelih od multiple skleroze.